DMN:FRA
Diamyd Medical AB
€ ०.०६१
arrow_upward
+०.१७%(+०.०००१०) 1D
नोभेम्बर १७, ०८:०५:२३ GMT+१ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
€ ०.०६
High
€ ०.०६
Low
€ ०.०६
Mkt. cap
१३.०० करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.८०
52-wk low
€ ०.०५
No. of employees
४२
Open
€ ०.०६
High
€ ०.०६
Low
€ ०.०६
Mkt. cap
१३.०० करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.८०
52-wk low
€ ०.०५
No. of employees
४२
News stories
From web sources and news partners
ChartMill
·
१ घण्टा पहिले
S&P 500 Premarket Movers on Nov. 17: Gainers and Losers
The Motley Fool
·
२५ मिनेट पहिले
Prediction: Dec. 9 Will Mark a Turning Point for the S&P 500
FOREX.com
·
१ घण्टा पहिले
S&P 500 forecast: Why US stocks have largely defied gravity and what could trigger a correction
Traders Union
·
४२ मिनेट पहिले
S&P 500 could deliver 18% total return by 2027, Goldman Sachs projects
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB